Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Natco Ups The Ante Lilly Readies Voluntary Licensing For Olumiant

Executive Summary

Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.

You may also be interested in...



Biden To Give Away 10% Of US COVID-19 Vaccine Supply As He Mulls Call For Patent Waiver

President Biden announced plans to increase vaccination in the US as members of Congress and industry press the administration to take steps to expand global access to COVID-19 vaccines. BIO proposes an alternative to the TRIPS waiver that would expedite export of raw materials and manufacturing supplies.

Natco Tests Compassionate Use Window In India For Merck’s COVID Pill

Natco seeks emergency approval in India for investigational therapy molnupiravir, currently being developed by Merck & Co for the treatment of non-hospitalized COVID-19 patients. The firm has linked its request to compassionate use amid a ferocious surge in COVID-19 cases in India, posing a potentially delicate choice for the regulator.

Lilly Faces India IP Challenges From Natco For Verzenio, Olumiant

Lilly’s anticancer abemaciclib and rheumatoid arthritis drug baricitinib, which has received a US EUA for COVID-19, have become targets of challenger Natco in India. The US giant says it's working closely with India’s health ministry to ensure access to patients who need its innovative therapies, amid indications Natco may be weighing plans to seek a voluntary license for baricitinib.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel